Associated tags: Radiation, Patient, Accuray, Cancer, Medical imaging
Locations: UNITED STATES, NEW JERSEY, EUROPEAN UNION, ILLINOIS, CHICAGO, WISCONSIN, SCOTLAND, CT
Cancer,
Congress,
IMRT,
Physics,
Cyberknife,
Health,
Tomotherapy,
Software,
Patient,
University,
Royal Marsden Hospital,
Radiation therapy,
Malignancy,
MBA,
Neuro,
Medical imaging MADISON, Wis., April 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024. The latest generation CyberKnife® and Radixact® platforms provide medical care teams with the technology necessary for expanding the curative power of radiation therapy and delivering on the focus of this year's congress, bridging the care gap. The European Society for Radiotherapy and Oncology's (ESTRO) annual meeting will take place May 3 to May 7, 2024, in Glasgow, Scotland.
Key Points:
- MADISON, Wis., April 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024.
- The European Society for Radiotherapy and Oncology's (ESTRO) annual meeting will take place May 3 to May 7, 2024, in Glasgow, Scotland.
- Accuray is a wellness focused organization, taking into account the patient's health and well-being throughout their treatment when prioritizing product enhancements.
- Uniformity in image quality and consistency in Hounsfield units validate their use in this important step in the radiation therapy treatment workflow.
Cancer,
Radiation treatment planning,
Risk,
Cyberknife,
Radiation,
Partnership,
Radiosurgery,
Neurosurgery,
DSM-IV codes,
Patient,
Faculty,
Health,
Quality of life,
Knowledge,
Nursing The Genolier based center is the most recent addition to the Accuray network of advanced training facilities with sites located strategically around the world to make it easier for medical care teams to obtain state-of-the-art clinical education.
Key Points:
- The Genolier based center is the most recent addition to the Accuray network of advanced training facilities with sites located strategically around the world to make it easier for medical care teams to obtain state-of-the-art clinical education.
- The Genolier training facility includes hands-on simulation facilities for the CyberKnife and Radixact Systems to be used for training and demonstrations, and meeting rooms equipped with the most advanced technologies to host seminars, workshops and educational events.
- The center sits within the Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA, whose grand opening will occur later this year.
- "People diagnosed with cancer rely on their medical team to recommend and deliver a personalized, precise and safe treatment for their specific condition.
Retrieved on:
Wednesday, April 17, 2024
MADISON, Wis., April 17, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m.
Key Points:
- MADISON, Wis., April 17, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m.
- ET on May 1, 2024.
- A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com .
- A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the fourth quarter of fiscal 2024.
Radiation,
Prostate cancer,
Disease,
Incidence,
Patient,
Rectum,
RSS,
Prostate,
Motion,
SBRT,
Quality of life,
Cyberknife,
MBA,
Neoplasm,
Accuray,
Movement,
Health,
Medical imaging MADISON, Wis., March 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of disease, as well as with those who were previously treated with radiotherapy – supporting the system's versatility and value to medical care teams.
Key Points:
- "An extensive number of peer-reviewed scientific manuscripts have been published reporting on CyberKnife prostate SBRT efficacy and tolerability.
- The system's precision enables clinicians to confidently treat the prostate gland, which is situated near the sensitive bladder and rectum, with SBRT.
- Provide a viable option with "a low incidence of short-term genitourinary (GU) and gastrointestinal (GI) toxicities" for reirradiation of locally recurrent prostate cancer2.
- For example, if the prostate moves during treatment the CyberKnife® System detects this movement and synchronizes the treatment delivery beam to the tumor's new position in real-time.
MADISON, Wis., March 4, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the 36th Annual Roth Conference. The management team is scheduled to take part in a fireside chat on Monday, March 18, 2024 at 12:30pm PST / 3:30pm EST.
Key Points:
- Company to Take Part in Fireside Chat Monday, March 18, 2024 at 12:30pm PST / 3:30pm EST
MADISON, Wis., March 4, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY ) announced today its participation in the 36th Annual Roth Conference.
- The management team is scheduled to take part in a fireside chat on Monday, March 18, 2024 at 12:30pm PST / 3:30pm EST.
- A live webcast of the fireside chat can be accessed on the Accuray website at investors.accuray.com .
- The 36th Annual Roth Conference will connect institutional investors with companies from diverse industry sectors.
Retrieved on:
Tuesday, February 27, 2024
MADISON, Wis., Feb. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference taking place March 12-13, 2024. The management team is scheduled to participate in a fireside chat on Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST.
Key Points:
- Company to Take Part in Fireside Chat Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST
MADISON, Wis., Feb. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference taking place March 12-13, 2024.
- The management team is scheduled to participate in a fireside chat on Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST.
- A live webcast of the fireside chat can be accessed on the Accuray website at investors.accuray.com .
- The Oppenheimer Conference will connect institutional investors to a wide variety of public and private healthcare companies spanning all major sectors of the healthcare industry.
MADISON, Wis., Feb. 5, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place on February 13, 2024.
Key Points:
- MADISON, Wis., Feb. 5, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place on February 13, 2024.
- BTIG-hosted events are intended for prospective and existing BTIG clients only.
- To request a one-on-one meeting with management, please contact your BTIG representative with interest.
Retrieved on:
Thursday, January 25, 2024
Cyberknife,
Artificial intelligence,
Neoplasm,
Patient,
Research,
Prostate cancer,
Health,
Partnership,
Radiosurgery,
Cancer,
Quality of life,
Gold,
Movement,
SBRT,
DSM-IV codes,
SRS,
Brain,
Estate (law),
Medical imaging MADISON, Wis., Jan. 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Providence Swedish Radiosurgery Center in Seattle, Washington is enhancing its cancer treatment capabilities with the purchase of the latest generation CyberKnife® S7™ System, the hospital's second CyberKnife radiation delivery device purchase. The precision and accuracy enabled by the system's robotic design will also make it an ideal choice for the treatment of neurologic disorders. The new system will enable the medical team to deliver gold standard stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments faster than with previous models, expanding access to an effective and convenient option to more patients.
Key Points:
- The precision and accuracy enabled by the system's robotic design will also make it an ideal choice for the treatment of neurologic disorders.
- "The Providence Swedish Radiosurgery Center began using their first CyberKnife System more than 10 years ago.
- "I couldn't be prouder that the Providence Swedish Radiosurgery team is continuing to invest in Accuray technologies.
- "At Providence Swedish Radiosurgery Center, we recognize that treatment decisions significantly impact patients' immediate health and long term quality of life.
Retrieved on:
Tuesday, January 16, 2024
MADISON, Wis., Jan. 16, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m.
Key Points:
- MADISON, Wis., Jan. 16, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m.
- ET on January 31, 2024.
- A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com .
- A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the third quarter of fiscal 2024.
Retrieved on:
Tuesday, December 5, 2023
MADISON, Wis., Dec. 5, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact® System in Japan beginning November 30, 2023.
Key Points:
- MADISON, Wis., Dec. 5, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact® System in Japan beginning November 30, 2023.
- The addition of this new feature will enable medical teams using the Radixact System to offer a wider range of radiotherapy treatment options using one device.
- SGRT technology, which helps confirm the patient is appropriately positioned to deliver radiation, is widely used to facilitate these treatments.
- "We are very pleased to now offer VitalHold to our customers to support surface-guided radiotherapy using the Radixact System.
